Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Palomar, Gillette renegotiate

This article was originally published in The Rose Sheet

Executive Summary

Firms have extended "launch decision" for a home-use, light-based hair removal device for women until no later than Feb. 29, 2008, according to Dec. 21 release. Palomar Medical Technologies says that under the existing development and license agreement - forged in February 2003 and amended and restated in February 2007 - Gillette was to make the launch decision by Jan. 7 (1"The Rose Sheet" Feb. 24, 2003, In Brief). However, companies have entered into negotiations for a new arrangement expected to include "the release of Palomar from exclusivity," in return for which "there would be a reduction in the percentage of net sales that Gillette pays to Palomar and a change from annual payments...to reduced calendar quarterly payments for a certain period," Palomar expects. There are no assurances that a new definitive agreement will be reached, the firm says, noting that the existing agreement could be terminated. L'Oréal also has been drawn to aesthetic devices; in December, the company announced a partnership with Light BioScience to co-develop stimulation devices for reducing wrinkles via light-emitting-diode photomodulation (2"The Rose Sheet" Dec. 17, 2007, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel